Kapila K. Anand - Mar 31, 2023 Form 4 Insider Report for Elanco Animal Health Inc (ELAN)

Role
Director
Signature
/s/ Catherine S. Powell, as Attorney-in-Fact for Kapila K. Anand
Stock symbol
ELAN
Transactions as of
Mar 31, 2023
Transactions value $
$28,750
Form type
4
Date filed
7/5/2023, 05:12 PM
Previous filing
Dec 2, 2022
Next filing
Jun 7, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELAN Deferred Stock Units Award $14.4K +1.53K +104.88% $9.40 2.99K Mar 31, 2023 Common Stock 1.53K Direct F1, F2, F3
transaction ELAN Deferred Stock Units Award $14.4K +1.43K +47.83% $10.06 4.42K Jun 30, 2023 Common Stock 1.43K Direct F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Ms. Anand elected to defer her director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock.
F2 The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan.
F3 The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $9.40 on March 31, 2023.
F4 The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $10.06 on June 30, 2023.